Skip to main content
main-content

Spondyloarthropathies

Medications

Certolizumab pegol shows promise for nonradiographic axSpA

The tumor necrosis factor inhibitor certolizumab pegol could be an option for patients with active nonradiographic axial spondyloarthritis and objective signs of inflammation, indicate phase III trial results.

15-03-2019 | Axial spondyloarthritis | Highlight | News

Certolizumab pegol shows promise for nonradiographic axSpA

The tumor necrosis factor inhibitor certolizumab pegol could be an option for patients with active nonradiographic axial spondyloarthritis and objective signs of inflammation, indicate phase III trial results.

13-03-2019 | Axial spondyloarthritis | News

Adding conventional DMARDs to TNF inhibitors may be beneficial for obese axSpA patients

Using conventional synthetic DMARDs in addition to tumor necrosis factor inhibitor therapy may result in an increased likelihood of clinical response among overweight and obese patients with axial spondyloarthritis, researchers report.

06-03-2019 | Psoriatic arthritis | News

Early TNF inhibitor initiation benefits patients with psoriatic arthritis

Initiating the tumor necrosis factor inhibitor golimumab at the same time as methotrexate almost doubles the rate of remission versus methotrexate monotherapy in patients with early psoriatic arthritis, study findings indicate.

22-02-2019 | Adalimumab biosimilar | News

EMA gives nod to two adalimumab biosimilars

The Committee for Medicinal Products for Human Use has recommended two new adalimumab biosimilars for approval in Europe.

Trials of JAK inhibitors in spondyloarthritis: A round-up

medwireNews rounds up the completed and ongoing clinical trials investigating JAK inhibitors in patients with spondyloarthritis.

21-02-2019 | Psoriatic arthritis | Feature | Article

The role of JAK inhibitors in the treatment of PsA

Dafna Gladman speaks to medwireNews about the trial data supporting the use of Janus kinase inhibitors in patients with psoriatic arthritis, and discusses the impact these agents may have.

21-02-2019 | Spondyloarthropathies | Feature | Article

Trials of JAK inhibitors in spondyloarthritis: A round-up

medwireNews rounds up the completed and ongoing clinical trials investigating JAK inhibitors in patients with spondyloarthritis.

The role of JAK inhibitors in the treatment of PsA

Dafna Gladman speaks to medwireNews about the trial data supporting the use of Janus kinase inhibitors in patients with psoriatic arthritis, and discusses the impact these agents may have.

08-02-2019 | Psoriatic arthritis | News

PRO results back tofacitinib use in PsA patients

Two post-hoc analyses published in RMD Open indicate that treatment with the Janus kinase inhibitor tofacitinib is associated with an improvement in patient-reported outcomes among individuals with psoriatic arthritis.

07-02-2019 | Psoriatic arthritis | News

Ixekizumab treatment linked to enthesitis, dactylitis improvements in PsA

A post-hoc analysis of the SPIRIT-P1 and SPIRIT-P2 trials suggests that treatment with ixekizumab is associated with improvements in enthesitis and dactylitis among patients with psoriatic arthritis.

01-02-2019 | Psoriatic arthritis | News

Unclear benefits of methotrexate highlighted for PsA patients

Findings from a systematic review suggest that methotrexate may offer some benefits for patients with psoriatic arthritis, but the quality of evidence is low.

29-01-2019 | Secukinumab | News

IBD ‘uncommon’ in patients treated with secukinumab

Inflammatory bowel disease is an “uncommon” occurrence among patients with psoriatic arthritis, ankylosing spondylitis, or psoriasis who are treated with the interleukin-17A inhibitor secukinumab, researchers report.

21-01-2019 | Ankylosing spondylitis | News

Trial results back TNF inhibitor dose-reduction strategy in ankylosing spondylitis patients

A dose-reduction strategy may be feasible for ankylosing spondylitis patients in sustained clinical remission with tumor necrosis factor inhibitor treatment, findings from the open-label REDES-TNF trial suggest.

03-01-2019 | Psoriatic arthritis | News

Support for methotrexate use in PsA patients

Findings from an observational study suggest that methotrexate treatment, with a dose-escalation strategy targeting remission, improves the joint and skin manifestations of psoriatic arthritis.

Serum calprotectin predicts relapse risk in TNFi-treated RA, PsA

Serum calprotectin levels independently predict relapse risk in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis who are in remission or have low disease activity, Spanish researchers report.

20-12-2018 | Rheumatoid arthritis | Highlight | News

Serum calprotectin predicts relapse risk in TNFi-treated RA, PsA

Serum calprotectin levels independently predict relapse risk in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis who are in remission or have low disease activity, Spanish researchers report.

19-12-2018 | Psoriatic arthritis | News

Abatacept may improve PROs in PsA patients

Treatment with abatacept is associated with improvements in patient-reported outcomes among individuals with psoriatic arthritis, study findings suggest.

Recognizing and managing cardiovascular risk in PsA patients

medwireNews speaks to Lihi Eder about why patients with psoriatic arthritis have elevated cardiovascular risk, and what can be done to mitigate it.

18-12-2018 | Psoriatic arthritis | Feature | Article

Recognizing and managing cardiovascular risk in PsA patients

medwireNews speaks to Lihi Eder about why patients with psoriatic arthritis have elevated cardiovascular risk, and what can be done to mitigate it.

image credits